ID: ALA519300

Max Phase: Preclinical

Molecular Formula: C28H33ClN6O2

Molecular Weight: 521.07

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Cc1cc(N2CCC(N(C)C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12

Standard InChI:  InChI=1S/C28H33ClN6O2/c1-17-13-21(35-11-8-20(9-12-35)34(2)3)15-23-26(17)33-27(32-23)25-22(7-10-30-28(25)37)31-16-24(36)18-5-4-6-19(29)14-18/h4-7,10,13-15,20,24,36H,8-9,11-12,16H2,1-3H3,(H,32,33)(H2,30,31,37)/t24-/m1/s1

Standard InChI Key:  HEBKCUAEAWNUQL-XMMPIXPASA-N

Associated Targets(Human)

Insulin-like growth factor I receptor 8605 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Cytochrome P450 3A4 53859 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Insulin-like growth factor 1 receptor 35 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mus musculus 284745 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 521.07Molecular Weight (Monoisotopic): 520.2354AlogP: 4.56#Rotatable Bonds: 7
Polar Surface Area: 100.28Molecular Species: BASEHBA: 6HBD: 4
#RO5 Violations: 1HBA (Lipinski): 8HBD (Lipinski): 4#RO5 Violations (Lipinski): 1
CX Acidic pKa: 9.75CX Basic pKa: 9.61CX LogP: 2.58CX LogD: 0.74
Aromatic Rings: 4Heavy Atoms: 37QED Weighted: 0.28Np Likeness Score: -1.09

References

1. Zimmermann K, Wittman MD, Saulnier MG, Velaparthi U, Langley DR, Sang X, Frennesson D, Carboni J, Li A, Greer A, Gottardis M, Attar RM, Yang Z, Balimane P, Discenza LN, Vyas D..  (2008)  Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.,  18  (14): [PMID:18572407] [10.1016/j.bmcl.2008.05.104]

Source